The group is the worlds largest translational pain research group with the primary focus on basic and applied human experimental and clinical pain research. Human pain bio-markers for induction and assessment of pain are developed and applied in basic human experimental studied, in mechanisms based drug profiling studies (phase I proof-of-concept experimental and clinical studies and phase II proof-of-concept clinical studies), and in clinical studies (acute pain, inflammatory pain, neuropathic pain, musculoskeletal pain, visceral pain, dysfunctional pain syndromes). A variety of surrogate pain bio-markers are developed and used for the purpose of mimicking symptoms in chronic pain patients.

 

The current network encounters research activities in 12 different countries and collaborative projects with 15 international pharmaceutical industries.